GlassScriptPhysician profile
Jenny Minton
NPI 1619590098
$6,223.32
in general payments reported to CMS, 2019-2025
58 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $1,735 · 2023: $2,293 · 2024: $1,863 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,254 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,253.85 |
| Education | $122.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $692.91 | 2022-2024 | |
| Pfizer INC. | $510.32 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $412.48 | 2022-2024 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $336.79 | 2022-2025 | Calquence, Imfinzi, Lynparza |
| Janssen Biotech, INC. | $299.78 | 2022-2024 | Darzalex, Tecvayli, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $299.55 | 2022-2025 | Iclusig, Ninlaro, Fruzaqla |
| Seagen INC. | $257.05 | 2021-2023 | Adcetris, Padcev |
| Celgene Corporation | $227.56 | 2022-2024 | Reblozyl, Opdualag, Pomalyst |
| Galt Pharmaceuticals, LLC | $212.59 | 2023 | Orphengesic Forte, Oravig |
| E.R. Squibb & Sons, L.L.C. | $195.74 | 2022-2024 | Opdualag, Augtyro, Opdivo |
| Astellas Pharma US INC | $164.39 | 2022-2025 | Xtandi, Padcev |
| Incyte Corporation | $149.25 | 2022-2024 | Jakafi, Monjuvi, Pemazyre |
| Exelixis INC. | $143.60 | 2022-2023 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $133.69 | 2022-2023 | Imbruvica, Epkinly |
| Amgen INC. | $130.39 | 2022-2023 | Lumakras, Kyprolis |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Minton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.